Evidence map›Paper›PMID 41543151›Full record

ReviewOncology reports2026

Role of tumor‑infiltrating lymphocytes and miR‑155 in breast cancer: Insights into carcinogenesis and their potential as prognostic biomarkers (Review).

Miriam Monteiro Alvares-Vilela, Franciele Schlemmer, Sabrina Simplício De Araújo Romero Ferrari, Mary-Ann Elvina Xavier, Ricardo Titze-De-Almeida

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Miriam Monteiro Alvares-VilelaTechnology for Gene Therapy Laboratory, Central Institute of Sciences, University of Brasília, Brasília 70910‑900, Brazil.
Franciele SchlemmerTechnology for Gene Therapy Laboratory, Central Institute of Sciences, University of Brasília, Brasília 70910‑900, Brazil.
Sabrina Simplício De Araújo Romero FerrariTechnology for Gene Therapy Laboratory, Central Institute of Sciences, University of Brasília, Brasília 70910‑900, Brazil.
Mary-Ann Elvina XavierTechnology for Gene Therapy Laboratory, Central Institute of Sciences, University of Brasília, Brasília 70910‑900, Brazil.
Ricardo Titze-De-AlmeidaTechnology for Gene Therapy Laboratory, Central Institute of Sciences, University of Brasília, Brasília 70910‑900, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

<p>Breast cancer is the most common cancer in the female population worldwide. The present review examines the biology of breast cancer, with a focus on the interplay between tumor‑infiltrating lymphocytes (TILs) and microRNAs (miRNAs or miRs). TILs, which reflect the immune system activity in combating tumors, are associated with more favorable prognoses and positive response to therapies. Elevated levels of TILs characterize lymphocyte‑predominant breast cancers (LPBCs), which are associated with higher therapeutic response rates in triple‑negative breast cancer, a type of LPBC. Defining the threshold for LPBCs presents a challenge: TIL levels ≥50% are associated with short‑term pathological complete response as well as long‑term overall and disease‑free survival; however, this percentage is not often achieved in clinical practice. Conversely, a lower threshold of 30% lymphocyte infiltration can predict favorable prognosis for anticancer therapy and allows for the identification of a broader range of patients. The tumor inflammatory landscape is regulated by miRNAs, particularly miR‑155. Elevated levels of miR‑155 are associated with the presence of TILs and a favorable inflammatory profile, leading to a tumor‑inflamed microenvironment. Moreover, miR‑155 is associated with various antitumoral immune cells, including CD8

Indexed as

Biomarkers, TumorBreast NeoplasmsLymphocytes, Tumor-InfiltratingMicroRNAsTriple Negative Breast NeoplasmsCarcinogenesisFemaleGene Expression Regulation, NeoplasticHumansPrognosisTumor MicroenvironmentBiomarkers, TumorMicroRNAsMIRN155 microRNA, humanbiomarkermicroRNA‑155triple‑negative breast cancertumor‑infiltrating lymphocyte

Identifiers

PMID41543151
PMCPMC12828645

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.